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Abstract
Macrophages (MQ) orchestrate inflammatory and reparatory processes in injured connective tissues but their role during
different phases of tendon healing is not known. We investigated the contribution of different MQ subsets in an equine
model of naturally occurring tendon injury. Post mortem tissues were harvested from normal (uninjured), sub-acute (3–6
weeks post injury) and chronically injured (.3 months post injury) superficial digital flexor tendons. To determine if
inflammation was present in injured tendons, MQ sub-populations were quantified based on surface antigen expression of
CD172a (pan MQ), CD14
highCD206
low (pro-inflammatory M1MQ), and CD206
high (anti-inflammatory M2MQ) to assess
potential polarised phenotypes. In addition, the Lipoxin A4 receptor (FPR2/ALX) was used as marker for resolving
inflammation. Normal tendons were negative for both MQ and FPR2/ALX. In contrast, M1MQ predominated in sub-acute
injury, whereas a potential phenotype-switch to M2MQ polarity was seen in chronic injury. Furthermore, FPR2/ALX
expression by tenocytes was significantly upregulated in sub-acute but not chronic injury. Expression of the FPR2/ALX
ligand Annexin A1 was also significantly increased in sub-acute and chronic injuries in contrast to low level expression in
normal tendons. The combination of reduced FPR2/ALX expression and persistence of the M2MQ phenotype in chronic
injury suggests a potential mechanism for incomplete resolution of inflammation after tendon injury. To investigate the
effect of pro-inflammatory mediators on lipoxin A4 (LXA4) production and FPR2/ALX expression in vitro, normal tendon
explants were stimulated with interleukin-1 beta and prostaglandin E2. Stimulation with either mediator induced LXA4
release and maximal upregulation of FPR2/ALX expression after 72 hours. Taken together, our data suggests that although
tenocytes are capable of mounting a protective mechanism to counteract inflammatory stimuli, this appears to be of
insufficient duration and magnitude in natural tendon injury, which may potentiate chronic inflammation and fibrotic
repair, as indicated by the presence of M2MQ.
Citation: Dakin SG, Werling D, Hibbert A, Abayasekara DRE, Young NJ, et al. (2012) Macrophage Sub-Populations and the Lipoxin A4 Receptor Implicate Active
Inflammation during Equine Tendon Repair. PLoS ONE 7(2): e32333. doi:10.1371/journal.pone.0032333
Editor: Martin Gerbert Frasch, Universite ´ de Montre ´al, Canada
Received September 29, 2011; Accepted January 25, 2012; Published February 22, 2012
Copyright:  2012 Dakin et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This research article was funded by Biotechnology and Biological Sciences Research Council (BBSRC) UK and Ceva (France) grant number BB/F018258/1.
The funders had no role in study design, data collection and analysis, decision to publish or manuscript preparation.
Competing Interests: SGD’s PhD is funded by Biotechnology and Biological Sciences Research Council (BBSRC) UK and Ceva (France). This does not alter the
authors’ adherence to all the PLoS ONE policies on sharing data and materials. The authors have declared that no other competing interests exist.
* E-mail: sdakin@rvc.ac.uk
Introduction
Pathologic changes in tendons due to repetitive use are a
significant cause of morbidity in humans, with Achilles tendon
injury rates of up to 56% amongst elite athletes [1,2]. The
corresponding tensile region of the equine superficial digital flexor
tendon (SDFT) is similarly susceptible to exercise induced
tendinopathy [3], which may be exacerbated by sudden overstrain
injury. The importance of inflammatory or degenerative processes
contributing to tendon injuries is subject to debate. In humans,
tendinopathy is described as a result of a primarily degenerative
condition, as inflammatory cells are rarely observed in histological
studies of over-strained or ruptured human tendons [4,5,6,7,8].
However, this may be attributable to factors such as the timing at
which human patients present themselves for examination, which
is usually at the later stages of injury (or with recurrent injury), and
the availability of tissues for examining at different times after
injury, precluding study of the early phases of tendon repair. In
naturally occurring equine tendinopathy, there is an initial
transient phase (days) of clinically evident inflammation (heat,
pain, swelling), which rapidly subsides [9]. The sub-acute phase
(weeks) is characterised by the resolution of symptomatic
inflammation and the onset of fibroplastic repair. In chronic
injury the repair continues for many months but in both man and
horse the normal architecture, composition and function of tendon
are never restored after injury [6,10,11].
Macrophages (MQ) are an important immune cell type involved
in both inflammatory and repair-processes. Indeed, MQ are
present in chronically injured samples of torn human supraspina-
tus tendon [12]. Furthermore, rodent models of surgically induced
tendon injury have been used to evaluate the presence of
inflammatory cells by immunohistochemistry [13,14]. In these
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cell infiltration, consisting of a rapid and transient accumulation of
neutrophils, followed by an increase in MQ infiltration between 1
and 28 days post injury in a rat model of Achilles tendon injury
[13]. Similarly, Wong and co-workers documented temporal
changes in inflammatory cell subsets in a murine immobilised
surgical adhesion model of injury, reporting peak neutrophil and
MQ accumulation 1–5 days and 21 days post surgery respectively
[14]. The requirement of MQ for adult tissue repair is supported
by the use of wound healing studies in murine MQ-knockout
models, with impaired healing responses observed in MQ deplete
wounds [15,16,17]. Although crucial for healing, MQ initially fulfil
a different function by secreting pro-inflammatory agents in
response to tissue damage, including interleukin-1-beta (IL-1b),
Tumour Necrosis Factor alpha (TNFa), bioactive prostaglandins,
reactive oxygen intermediates and many proteases [18]. These
factors have been shown to act as important initiators of the
tendinopathic cascade [19,20,21,22], which may drive matrix
metalloproteinase (MMP) mediated catabolism of tendon extra-
cellular matrix [21,22,23].
In order to identify MQ in normal and injured tendons we
selected CD172a, as this antigen has been used to successfully
identify MQ in ovine [24] and equine [25] tissues. The unique
plasticity in function of MQ can in part be attributed to different
subsets/phenotypes. MQ have the capacity to exist in at least two
functionally distinct phenotypic states, differing in their cell surface
receptor expression, effector function and cytokine production
[26,27,28,29]. M1 polarised (classically activated) MQ appear to
show a pro-inflammatory response pattern, whilst M2 (alterna-
tively activated) MQ dampen inflammatory responses by produc-
ing immunosuppressive cytokines such as IL-1 receptor antagonist
(IL-1Ra), IL-10, IL-4 and IL-13 [28]. Expression of both M1 and
M2 MQ markers is reported in circulating peripheral blood
mononuclear cells [30,31]. M1MQ surface antigens include CD14
[32,33,34], CD16, CD32, CD64, CD80 and CD86 [28], but not
the markers of M2MQ polarisation which include the mannose
receptor (MR) CD206 and CD163 [28,30,34]. Therefore,
M1MQ express CD14, but not CD206 i.e. (CD14
highCD206
low),
whereas M2MQ express CD206 but not necessarily CD14
(CD14
lowCD206
high) and so this combination of surface antigens
permits identification of the predominating MQ phenotype. The
temporal changes in MQ phenotype influence synthesis of the
extracellular matrix of the injured tissue throughout the different
phases of wound healing [16,35]. Furthermore a correlation
between the degree of inflammation and development of
subsequent fibrosis has been reported, which is thought to be a
MQ mediated progression [36].
Despite evidence suggesting that excessive inflammation causes
damage to connective tissues by initiating the fibrotic repair that
ensues, total inflammatory blockade may not necessarily be
beneficial for wound healing processes [37,38]. An intriguing
dimension to the physiology of inflammation is the identification of
specialised pro-resolving mediators (SPM) encompassing lipoxins
such as lipoxin A4 (LXA4) [39] acting upon FPR2/ALX
(previously termed FPRL1 or ALXR) [40] and more recently,
the resolvins, protectins and maresins [41,42]. FPR2/ALX is
expressed by monocytes and MQ [43] and is central to controlling
the duration and magnitude of the inflammatory response by
modulating leukocyte adherence and chemotaxis, and in so doing
provides ‘endogenous stop signals’ for inflammation [44].
Although stereoselective for LXA4, FPR2/ALX is a multi-
recognition receptor [45], to which the anti-inflammatory protein
Annexin A1 (ANXA1) also binds [46,47,48]. Annexin A1 is also
implicated in the resolution of inflammation, with additional
important roles in phagocytosis and apoptosis [49,50]. These
resolving pathways are programmed responses activated during
inflammation, demonstrating critical roles in the switching of lipid
mediators from the prostanoid to the lipoxin axis in order to
promote resolution of inflammation and the return of tissues to
their normal homeostatic state [39,44,51,52,53]. Despite the
anticipated importance of MQ, SPMs and Annexin A1 in healing
tendons, there is limited information documenting their presence
in the early stages of tendon injury. The presence of SPMs has not
been previously assessed in tendons, although studies in other
inflamed connective tissues have emphasised their importance in
resolving inflammation, including inhibition of neutrophil and MQ
recruitment and modification of vascular permeability [44].
Based on the similarities between tendon healing in horses and
humans [54,55], studies in naturally occurring equine tendino-
pathy may be physiologically representative of equivalent injury in
humans. For example, aging of the tendon matrix is believed to be
an important contributing factor to the development of tendino-
pathy [56,57], yet the effects of aging are restricted in rodent
models in contrast to those species displaying more evident aging
phenotypes such as horse and man [58,59,60]. Moreover, the
strain experienced during peak loading of the elastic energy storing
tendons in equine and human Achilles tendon in vivo far exceed
those sustained by rodent models [54,61,62]. Furthermore, re-
injury of chronically diseased tendons is common during
rehabilitation of patients with tendinopathy, a scenario which is
difficult to recapitulate in murine models of tendon injury. Thus
analysis of injured equine tendon, particularly during the early
phase of injury, presents a more appropriate and readily attainable
source than the human counterpart, and analysis of naturally
diseased tissues may be more representative than induced models
of tendon injury [63,64]. Our analysis provides evidence for
potential changes in MQ sub-populations, FPR2/ALX and
Annexin A1 expression during stages of flexor tendon healing
compared to normal (uninjured) tendons. Upregulation of FPR2/
ALX expression by tenocytes in sub-acute injury in vivo was
supported by in vitro experiments assessing the effect of pro-
inflammatory mediators on tendon.
Results
Macroscopic and microscopic analysis of injured equine
tendons
Normal SDFT’s (Fig. 1A) were smaller in size compared to sub-
acutely injured tendons, which exhibited a central core of
haemorrhagic granulation tissue and disruption of the fascicle
arrangement (Fig. 1B). Chronically injured tendons were also
enlarged compared to normal and exhibited a thickened fibrosed
paratenon (Fig. 1C). By this stage granulation tissue was absent but
the highly organised fascicular arrangement present in normal
tendon was not restored. Histology of normal equine SDFT’s
showed a highly organised and regular arrangement of parallel
collagen fibrils with tenocytes (tendon fibroblasts) arranged along
and between the fibrils (Fig. 1D). In contrast, sub-acutely injured
tendons exhibited neovascularisation and fibroplasia, with dis-
rupted collagen fibril organisation and marked increased cellular
infiltration (Fig. 1E). Chronically injured tendons (Fig. 1F)
displayed more regular arrangement of collagen fibrils, with well
established neo-vascularisation, reactive fibroplasia and increased
cellular infiltration with MQ localised to peri-vascular and
endotenon regions (Fig. 2A–C). In chronic injury, MQ were also
located at the interface between the site of previous injury and the
adjacent more normal tendon (Fig. 2D).
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macrophage polarity
Images for the positive, negative and isotype controls for all
antibodies were validated on cryosections of equine spleen and are
shown in Fig. 3 A–F. Co-expression of CD14 and CD206
(demonstrated by yellow staining) was not identified in sub-acute
or chronic injured tendons in contrast to equine spleen (Fig. 3 B).
Immunostaining for the pan MQ marker CD172a on cryosections
derived from normal, sub-acute and chronic injured SDFT’s (Fig.4
A–C) revealed a greater number of MQ in sub-acutely injured
SDFT compared to normal SDFT (P=0.008), with fewer MQ
present in chronic injured tendons (Fig. 5A). Dual labelling using
antibodies to CD14 and CD206 facilitated characterisation of MQ
sub-populations through the stages of tendon healing (Fig. 6 D–F).
There was a significantly greater proportion of M1MQ phenotype
(CD14
highCD206
low) in sub-acute injury compared to chronic
injured SDFT (P=0.01) (Figs. 5B, 6E and 7A). In contrast, the
M2MQ phenotype (CD14
lowCD206
high) was predominant during
the chronic injury phase (Figs. 5C, 6F and 7B); these cells were
located in the peri-vascular and endotenon regions. To facilitate
direct comparison of MQ phenotypes during sub-acute and
chronic injury phases, a ratio of areas (mm
2) of positive immuno-
reactivity for M1:M2 MQ was derived. This showed predominance
of the M1 polarised MQ phenotype in sub-acute injury compared
to chronic injury (P,0.001) (Fig. 5D).
Expression of FPR2/ALX is upregulated during the
sub-acute phase of tendon injury
To assess whether changes in MQ subsets are accompanied by
changes in FPR2/ALX expression, we next analysed expression of
this protein in the same normal, sub-acute and chronic injured
SDFT samples (Fig. 6 G–I). There was significantly greater FPR2/
ALX expression in sub-acute but not chronic injured SDFT
compared to normal tendons (P=0.01) (Fig. 8A). When separated
into the early and late stages of sub-acute injury, there was a
significant decline in FPR2/ALX expression with increasing time
after injury (P=0.03, r
2=0.82 Fig. 8B), which may account for the
large range of FPR2/ALX expression across this group. FPR2/
ALX was expressed on cytoplasmic processes of tenocytes of sub-
acutely injured tendons (Fig. 6H) but not by M1MQ, as verified by
dual labelling for CD14 and FPR2/ALX on tendon sections
(Fig. 7C).
Figure 1. Typical macroscopic appearance of normal and injured equine flexor tendons. (A) Normal superficial digital flexor tendon
(SDFT) from a 12 year old horse; (B) sub-acutely injured SDFT 3 weeks post injury from a 4 year old horse, exhibiting a haemorrhagic granular central
core (arrow) and (C) chronically injured SDFT .3 months post injury with a thickened fibrosed paratenon (arrow) from a 12 year old horse. Scale bar
for macroscopic images=1 cm. Corresponding longitudinal histology sections stained with Haematoxylin and Eosin: (D) normal SDFT showing
regular arrangement of collagen fibrils (arrow); (E) sub-acutely injured SDFT with marked cellular infiltration (black arrow) and haemorrhage (white
arrow); (F) chronically injured SDFT with increased cellularity in peri-vascular regions (arrow). Histology scale bar=12.5 mm.
doi:10.1371/journal.pone.0032333.g001
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PLoS ONE | www.plosone.org 3 February 2012 | Volume 7 | Issue 2 | e32333Figure 2. Haematoxylin and Eosin stained longitudinal histology sections of chronic injured SDFT (.3 months post injury) from a 7
year old horse (A, B and D). (A) Reactive fibroplasia with increased cellularity in peri-vascular region (arrows). Scale bar=100 mm. (B) Higher
magnification of (A) showing presence of macrophages (arrowheads) in peri-vascular areas. Scale bar=20 mm. (C) Corresponding 3-dimensional
reconstructed Z stack image of dual antibody labelling for CD14 (red) and CD206 (green). Blue represents Hoechst nuclear counter stain. White
arrows show CD14
lowCD206
high M2MQ located in peri-vascular endotenon regions. Scale bar=20 mm. (D) Histological appearance of more normal
SDFT to the right of the image (straight arrow) in contrast to irregular arrangement of collagen fibrils on the left (dashed arrow). The linear interface
between more normal and injured zones of tendon is demarcated by an area of increased cellularity containing macrophages (arrowhead).
Scale bar=50 mm.
doi:10.1371/journal.pone.0032333.g002
Figure 3. Representative Z stack images of antibody control cryosections of equine spleen. Panel A–C represents positive controls for:
(A) CD172a MQ (green); (B) Dual antibody labelling with CD14 (M1MQ red) and CD206 (M2MQ green) showing co-expression of both markers
(CD14
highCD206
high) in splenic monocytes/macrophages; (C) Lipoxin A4 receptor (FPR2/ALX, green). Panel D–F represents negative controls,
consisting of murine isotype matched primary control antibodies: (D) IgG1, (E) IgG2a, (F) IgG1 and IgG2a. Blue represents Hoechst nuclear counter stain.
Scale bar=12 mm.
doi:10.1371/journal.pone.0032333.g003
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As FPR2/ALX was absent in normal SDFT, but present during
sub-acute and chronic injury, we next assessed whether FPR2/
ALX expression was influenced by the presence of pro-
inflammatory mediators that are known to be upregulated in
tendon injury. We used an in vitro tendon explant model, whereby
macroscopically normal explants were stimulated with IL-1b and
PGE2, either alone or in combination, and analysed FPR2/ALX
expression over time. Representative images for FPR2/ALX
expression 72 hours post stimulation and average data for tendon
explants from the 3 horses are shown in Fig. 9. There was a
significant effect of time (P,0.001) and experimental condition
(P=0.01) on FPR2/ALX expression. FPR2/ALX expression was
at baseline or low level between 0–72 hours in non-stimulated
control tendon explants. Stimulation with IL-1b alone or in
combination with PGE2 significantly increased FPR2/ALX
expression by tenocytes compared to non-stimulated controls at
24 hours (P=0.049 and P=0.02 respectively). In contrast there
was no significant effect of PGE2 in isolation at this time point.
Maximal FPR2/ALX expression occurred 72 hours after stimu-
lation with either IL-1b or PGE2 compared to controls (P=0.002
and P=0.01 respectively). Combined stimulation with both
mediators also resulted in increased FPR2/ALX expression
compared to controls at 72 hours (P=0.02); however this was
Figure 4. Panel of representative 3-dimensional reconstructed Z stack immunofluorescent low magnification images of equine
SDFT sections. Pan MQ (CD172a) staining is shown for is for (A) normal, (B) sub-acute and (C) chronic injured tendons. Immunopositive cells are
green; blue represents Hoechst nuclear counter stain. Scale bar=20 mm.
doi:10.1371/journal.pone.0032333.g004
Figure 5. Box plots illustrating ratios of areas (mm
2) of immunopositive cells: counterstained nuclei. (A) CD172a pan MQ in normal
(uninjured), sub-acute and chronic injured equine tendons; (B) CD14
high (M1MQ) and (C) CD206
high (M2MQ) expression in sub-acute and chronic
injured tendons respectively. (D) Log transformed ratio of areas of positive immuno-reactivity for M1:M2 MQ from dual labelled CD14 and CD206
sections of sub-acute and chronic injured tendons. SAI=sub-acute injury (n=5), CI=chronic injury (n=5), N=normal tendon (n=5). All values
represent median with maximum and minimum range. *** P,0.001, ** P,0.01, * P,0.05.
doi:10.1371/journal.pone.0032333.g005
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with either mediator alone.
Effect of pro-inflammatory mediators on lipoxin A4
release in media
In addition to assessing the effect of pro-inflammatory mediators
on FPR2/ALX expression in tendon explants in vitro, we also
investigated their effect upon the release of LXA4 into tissue
culture media. LXA4 production was at baseline or low level
(,15 pg/ml) between 0–72 hours in media from non-stimulated
control explants. Stimulation with IL-1b induced maximal LXA4
release 24 hours post stimulation compared to controls (6-fold
increase, P,0.001) but returned to baseline levels at 72 hours. In
contrast, LXA4 levels increased maximally at 72 hours after PGE2
stimulation compared to controls (3-fold increase, P=0.048)
(Fig. 10).
Figure 6. Panel of representative 3-dimensional reconstructed Z stack immunofluorescent images of equine SDFT sections. (A–C)
CD172a MQ antibody, immunopositive cells are green; (D–F) Dual antibody labelling for CD14 (M1MQ red) and CD206 (M2MQ green) showing
CD14
highCD206
low MQ in sub-acute injury (E) and CD14
lowCD206
high MQ in chronic injury (F); (G–I) FPR2/ALX, immunopositive cells are green. Arrow in
panel H shows FPR2/ALX expression on tenocyte cytoplasmic extensions. Panels A, D, & G are from normal uninjured tendon; B, E & H are from sub-
acutely injured tendon; C, F & I are from chronically injured tendon. Blue represents Hoechst nuclear counter stain. Scale bar=12 mm.
doi:10.1371/journal.pone.0032333.g006
Figure 7. Panel of representative 3-dimensional reconstructed Z stack immunofluorescent images of injured SDFT sections. (A) Dual
labelled CD14 (red) and CD206 (green) showing predominance of CD14
high MQ in sub-acute tendon injury. Scale bar=20 mm. (B) Dual labelled CD14
(red) and CD206 (green) showing predominance of CD206
high MQ in chronic tendon injury. Scale bar=20 mm. (C) Dual labelled CD14 (red) and FPR2/
ALX (green), showing FPR2/ALX expression by tenocytes but not M1MQ in sub-acute tendon injury. Scale bar=12 mm. (D) Dual labelled CD14 (red)
and Annexin A1 (green), showing Annexin A1 expression by tenocytes but not M1MQ in sub-acute tendon injury. Scale bar=20 mm. Blue represents
Hoechst nuclear counter stain.
doi:10.1371/journal.pone.0032333.g007
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injury
Annexin A1 is also a ligand for FPR2/ALX with additional
roles in inflammation, resolution and apoptosis. To assess
expression of Annexin A1 in tendon injuries, we next analysed
expression of this protein in the same normal, sub-acute and
chronic injured SDFT samples. Annexin A1 expression was
restricted to tenocytes in injured tendons and not M1MQ, as co-
expression of these markers was not observed (Fig. 7D). Annexin
A1 expression was significantly increased in both sub-acute and
chronic injured tendons compared to normal samples, which
showed very low level expression (P,0.01) (Fig. 11).
Discussion
In the present study, we describe changes in MQ subsets, FPR2/
ALX and Annexin A1 expression in the sub-acute and chronic
phases of equine flexor tendon injuries. Our study illustrates that
the number of MQ significantly increase in sub-acutely injured
equine flexor tendons (3–6 weeks post injury) in contrast to their
absence in normal uninjured tendon. When the injury progressed
from sub-acute to the chronic injured stage, there was a potential
shift from a pro-inflammatory M1MQ (CD14
highCD206
low)t oa n
anti-inflammatory M2MQ (CD14
lowCD206
high) phenotype. Fur-
thermore, tendon injury led to an up-regulation of FPR2/ALX in
tenocytes in the sub-acute injury stage, which is likely to be
mediated by the production of pro-inflammatory mediators by
either tenocytes or infiltrating MQ. Annexin A1 expression was
also significantly increased in sub-acute and chronic tendon
injuries compared to normal tendons. Our study provides novel
data illustrating components of inflammation are highly active
during both the early and chronic stages of naturally occurring
equine flexor tendon injury, which have not been described during
the early phase of equivalent injury in man. Similarly, it is not
possible to recapitulate chronic injury or re-injury using induced
models of murine tendon injury, and may be more appropriate
from a therapeutic perspective.
Figure 8. FPR2/ALX expression in normal and injured equine tendons. (A) Box plot illustrating ratio of areas (mm
2) of immunopositive cells:
counterstained nuclei of expression of the Lipoxin A4 receptor (FPR2/ALX) in normal (N, n=5), sub-acute (SAI, n=5) and chronic injured (CI n=5)
equine tendons. Values represent median with maximum and minimum range. * P,0.05. (B) FPR2/ALX expression in sub-acutely injured tendons
(n=5) showing significant decline in FPR2/ALX protein expression with time after injury (P=0.03, r
2=0.82).
doi:10.1371/journal.pone.0032333.g008
Figure 9. Panel of representative 2-dimensional images illustrating FPR2/ALX expression in tendon explants showing non-
stimulated (vehicle only) control compared to explants stimulated with 5 ng ml
21 IL-1b and 1.0 mM PGE2 either alone or in
combination. Immunopositive staining is green, with Hoechst nuclear counter stain in blue. Scale bar=12 mm. Graph showing the effect of pro-
inflammatory mediators on tendon FPR2/ALX expression in vitro. Data represent average FPR2/ALX expression in tendon explants derived from 3
normal (uninjured) horses, whereby 2 replicates were analysed for each experimental condition and time point per horse. FPR2/ALX expression was
determined at time points 0, 12, 24 and 72 hours after stimulation and compared to non-stimulated controls. Significant up-regulation of FPR2/ALX
occurs 24 hours after stimulation with IL-1b or a combination of both mediators, and maximally 72 hours after stimulation with IL-1b, PGE2 or
combination of both mediators compared to controls. ** P,0.01, * P,0.05. Error bars denote SEM.
doi:10.1371/journal.pone.0032333.g009
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repair are well documented in other healing connective tissues
[65,66]. MQ are responsible for executing specific functions during
the diverse phases of wound repair as suggested by sub-optimal
wound healing in MQ deficient injured sites [67] and murine
knockout models [15,68]. Deficiency of MQ, particularly during
the early stage of repair has profound adverse effects on healing,
including reduced granulation tissue formation and impaired
epithilialization [16]. The plasticity and functional polarisation of
tissue MQ that we observed in injured tendon was similar to that
reported in skin repair [16]. Fully polarised M1 and M2 MQ have
been described as the extreme phenotypes of a continual spectrum
of functional states [28]. The greater proportion of M1MQ
polarised phenotypes (CD14
highCD206
low) in sub-acute compared
to chronic injury was indicative of the highly pro-inflammatory
status of recent injury in the sub-acutely injured tendon samples.
The predominance of M2MQ (CD14
lowCD206
high) in chronic
tendon injury suggests a potential phenotype or population
change. Although we have not investigated the nature of the
stimulus governing the fate of the M1MQ, this has been suggested
to occur by either apoptosis or lymphatic clearance [69]. We
observed M2MQ in peri-vascular and endotenon regions, and at
the interface between the previously injured area and adjacent
more normal tendon, a site which is prone to re-injury due to
disparate tissue biomechanical properties at this interface [11]. We
hypothesise that M2MQ in this region are actively surveying the
healing tendon for ‘stress signals’ in order to protect this
susceptible region from re-injury. It is likely that cyclical loading
sustains an inflammatory response that M2MQ fail to adequately
resolve, resulting in the development and accumulation of
localised collagen fibril damage (micro-lesions) during exercise
rehabilitation. This innate failure to resolve inflammation may
increase the propensity for fibrotic repair of adult connective
tissues in contrast to the abilities of macrophage deficient foetal
wounds that heal with minimal scar formation [16,36]. Thus the
persistence of MQ appears to be correlated with the deposition of
scar tissue at the site of injury in tendons. We did not observe co-
expression of CD14 and CD206 in the injured tendon sections
analysed. This may reflect the presence of specific sub-sets of
differentiated tissue MQ in tendon, because co-expression was
Figure 10. The effect of pro-inflammatory mediators on release
of lipoxin A4 (LXA4) in media from tendon explants. Data
represent average LXA4 levels from 3 normal (uninjured) horses. LXA4
levels were determined at time points 0, 12, 24 and 72 hours after
stimulation and compared to non-stimulated controls. There was a
difference in the temporal response showing increased LXA4 release
24 hours after stimulation with IL-1b (P,0.001) and 72 hours after
stimulation with PGE2 (P=0.048) compared to non-stimulated controls.
Values for significance were based on a linear model.
doi:10.1371/journal.pone.0032333.g010
Figure 11. Panel of representative 3-dimensional reconstructed Z stack immunofluorescent images of equine SDFT sections.
Annexin A1 (ANXA1) staining is shown for is for (A) normal, (B) sub-acute and (C) chronic injured tendons. Immunopositive cells are green; blue
represents Hoechst nuclear counter stain. Scale bar=20 mm. Box plot shows significantly increased Annexin A1 expression in sub-acute and chronic
injured tendons compared to low level expression in normal tendons. SAI=sub-acute injury (n=5), CI=chronic injury (n=5), N=normal tendon
(n=5). Values represent median with maximum and minimum range. * P,0.05.
doi:10.1371/journal.pone.0032333.g011
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monocytes as previously described [30,31].
FPR2/ALX is reported to have a central role in controlling the
duration and magnitude of the inflammatory response [44,70].
Although FPR2/ALX expression has not previously been
described in tendon, our study shows significant upregulation of
FPR2/ALX expression on tenocytes in the sub-acute phase of
injury, with lower level expression in chronic injury and not
detectable in normal (uninjured) tendon. The binding of LXA4 to
FPR2/ALX on tenocytes may enhance paracrine related
reprogramming of cytokine primed M1MQ [71], facilitating the
potential phenotypic switch we observed during tendon healing.
Indeed, endogenous LXA4 circuits are cited as regulators of
inflammatory angiogenesis and neovascularisation [72], both of
which are also prominent clinical features of early stage equine
tendinopathy. FPR2/ALX has been reported to be expressed on
circulating monocytes and MQ [40], but we were unable to show
expression on M1MQ in dual labelled sections of sub-acutely
injured tendons. The apparent absence of FPR2/ALX expression
on M1MQ may be attributable to phenotypic changes that occur
in the transition from infiltrating monocytes at injured sites to
differentiated tissue MQ [73]. We speculate diminished FPR2/
ALX expression by MQ may contribute to the defective healing
that occurs in injured tendons.
We also identified tenocytes expressing Annexin A1 (an
additional ligand for FPR2/ALX) in sub-acute and chronic
injured tendons. Annexin A1 has not been previously described
in tendon; however it is reported to act as an endogenous anti-
inflammatory mediator complimenting the actions of lipoxins,
potentiating resolution of inflammation via FPR2/ALX [74].
Furthermore, as Annexin A1 is also implicated in promoting pro-
apoptotic mechanisms [75], its presence in tendon may have an
additional role in the identification of damaged tenocytes that are
to be removed by MQ after injury. As Annexin A1 protein was
significantly upregulated in both sub-acute and chronic phases of
tendon injury, it would appear that inflammation and apoptosis
continue for a prolonged period after initial injury and throughout
tendon healing and remodelling.
Regulation of FPR2/ALX by pro-inflammatory mediators has
not been previously reported in wound healing, although
transcription of FPR2/ALX was shown to be upregulated by IL-
13, IL-4, IL-6 and IL-1b in human enterocytes [76]. In our study,
stimulation of normal tendon explants with IL-1b or PGE2
induced maximal release of LXA4 at 24 and 72 hours respectively,
compared to non-stimulated controls. The differences in kinetics
seen are potentially attributed to differences in receptor involve-
ment and subsequent down-stream signalling between IL-1b and
PGE2 [77,78,79], or the class switching of arachadonic acid
derived eicosanoids from prostaglandins towards production of
LXA4 [52]. Alternatively, these data may suggest that IL-1b is a
more potent activator of LXA4 than PGE2, as peak LXA4 release
coincided with the observed upregulation of FPR2/ALX expres-
sion at 24 hours and maximally at 72 hours after stimulation with
IL-1b. Interestingly, combined stimulation with both mediators
did not significantly increase FPR2/ALX expression compared to
using either mediator in isolation. The lack of an additive effect of
the two pro-inflammatory mediators may suggest maximal FPR2/
ALX transcription level is attained by stimulation with either
mediator alone, and we speculate that this may be a mechanism to
tightly regulate this gene.
M1MQ are reported to secrete pro-inflammatory agents such as
IL-1b and PGE2 [18,28]. In support of our in vitro experimental
findings, the presence of M1MQ also coincided with FPR2/ALX
up-regulation in naturally occurring early stage tendon injury.
Hence, FPR2/ALX may be acting in an endogenous protective
capacity to limit the degree of damage to the extracellular matrix
of recently injured tendon. However the decline in FPR2/ALX
expression in the late sub-acute stage of tendon injury suggests it is
possible that the duration and magnitude of FPR2/ALX
expression are insufficient to promote complete resolution of
inflammation in injured tendon, which may contribute to the
development of chronic inflammation and fibrotic repair
[46,69,71]. As M2MQ in chronic injury produce IL-1RA [28],
reduced FPR2/ALX expression in chronic compared to sub-acute
injury may be attributable to the reduced IL-1b effects on tendon.
Improved understanding of inflammation is crucial to the
development of novel anti-inflammatory agents that both preserve
the beneficial, yet enhance removal of the detrimental components
of the cascade. It is possible that augmenting resolution by
‘tricking’ chronically inflamed tissues into a resolving pathway
using potential new therapeutic targets such as lipoxins and other
FPR2/ALX agonists [46,80,81] may reduce the propensities for
fibrotic tendon repair and re-injury.
The categorisation of injury stage in this study was based on
known clinical history and post mortem examination, which may
not account for the presence of sub-clinical inflammatory processes
that occur prior to the onset of clinical disease, either in older
animals or those subjected to higher levels of exercise. We believe
that our present study contributes to the evidence that whilst
symptomatic inflammation is only subtle and transient in
tendinopathies, the regulatory components of the inflammatory
response in early stage tendinopathy are in fact highly active at the
cellular level. Consequently, prolonged subclinical inflammation
can potentially develop into symptomatic injury if sufficient
extracellular matrix microdamage accumulates. The ability to
determine the nature of the MQ phenotype and FPR2/ALX status
of sub-clinically injured tendon would provide valuable insight to
the inflammatory processes occurring prior to the onset of clinical
disease; however this is currently precluded by our inability to
accurately identify sub-clinical injuries in vivo. Future research
should aim to identify parameters that determine the inflamma-
tory and resolution status of injured tendon in vivo, such that sub-
clinical injury can be identified and treated prior to onset of
clinical disease.
Materials and Methods
Ethics Statement
Ethics approval for the collection of post mortem equine
tendons from an abattoir or local equine veterinary referral
hospital for this study was sought and approved from the Ethics
and Welfare Committee at the Royal Veterinary College (URN
2011 1117). No horses were euthanased for obtaining tissues for
the purposes of this study and all tendons were harvested after
informed consent had been obtained.
Collection and processing of equine tendons
Equine forelimbs (normal, without tendon injury; n=5, mean
age 863.5 years) were obtained from a UK abattoir and the
tensile region of the SDFT was dissected within 4 hours of death.
Tendons were classified as normal based on their macroscopic post
mortem appearance which included lack of visible signs of swelling
of the tendon body and a consistent pattern of fascicles on
transverse sections. Sub-acute (history of injury 3–6 weeks old;
n=5, mean age 1064.8 years) and chronically injured tendons
(.3 months post injury; n=5, mean age 1364 years) were
sourced from either an abattoir or a local equine veterinary
referral hospital and similarly processed. Tendon injuries were
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owner or referring veterinary surgeon prior to euthanasia of the
horse. All harvested tendons were obtained from Thoroughbred or
Thoroughbred cross breed horses aged between 4 and 16 years.
Tendon pieces from the mid-tensional regions were embedded in
optimal cutting temperature compound (OCT, Sakura Tissue-
TekH, Alphen aan den Rijn, The Netherlands) and snap frozen in
pre-chilled (280uC) n-hexane and stored at 280uC until processed
for histological or immunofluorescent analysis. Serial sections (8–
10 mm thickness) were cut on a cryostat (Bright, Cambridge, UK)
and mounted onto poly-L-lysine coated slides (VWR, Lutterworth,
UK) and allowed to dry for 2 hours at room temperature prior to
storage at 280uC.
Haematoxylin & Eosin staining of tendon cryosections
Tendon cryosections were fixed in chilled (4uC) acetone for
5 minutes and then allowed to air dry for 30 minutes. Sections
were hydrated in Phosphate Buffered saline (PBS) and stained with
Gills III Haematoxylin (Sigma Aldrich, Dorset, UK) for 3 minutes
and then washed with running water for a further 3 minutes.
Slides were stained with alcoholic Eosin (Sigma Aldrich,) for
40 seconds and rinsed with water. After dehydration and a final
rinse using Histosol
TM histological clearing agent (National
Diagnostics, Hull, UK), slides were mounted using DPX mounting
medium (BDH, Poole, UK).
Detection and characterization of macrophages, FPR2/
ALX and Annexin A1 in normal and injured equine
tendons
Cryosections of equine spleen were used as positive control
tissue to validate suitability and dilution of antibodies for use on
tendon sections. Negative controls consisted of spleen and sub-
acutely injured SDFT cryosections incubated with murine isotype
matched primary control antibodies (Southern Biotech, Birming-
ham, AL, USA). Subsequently, consecutive cryosections of normal
and injured equine tendons were probed using mouse anti-human
monoclonal antibodies to CD172a (pan MQ marker, IgG1,
VMRD, Pullman WA, USA), CD14 (M1 polarised MQ pheno-
type, IgG2a, BioLegend, Cambridge, UK), CD206 (M2 polarised
MQ phenotype, IgG1, AbCam, Cambridge, UK), FPR2/ALX
(Lipoxin A4 receptor, IgG1, AbCam, Cambridge) and Annexin A1
(IgG1, Abcam, Cambridge). Although CD172a is also a granulo-
cyte marker, we verified that granulocytes were not present using
Haematoxylin & Eosin stained cryosections of sub-acute and
chronic injured tendons. After warming cryosections at room
temperature for 30 minutes, sections were rehydrated in 1% PBS-
Tween 20 (PBS-T) and blocked in PBS containing 5% normal
goat serum (Sigma Aldrich) for 1 hour in a humid chamber at
room temperature. This was followed by incubation with the
primary antibody in PBS containing 5% normal goat serum for
2 hours, diluted either 1:100 or 1:50 (CD206). After 365 minute
washes in PBS-T, sections were incubated with the respective goat
anti-mouse secondary antibodies conjugated with either Alexa-
FluorH 488 IgG, Alexa FluorH 594 IgG2a (Invitrogen, Paisley,
UK), or goat anti-mouse IgG1-R-PE (Southern Biotech), each
diluted 1:300 in PBS containing 5% normal equine serum (Sigma
Aldrich) for 2 hours. To visualise the nuclei, slides were
subsequently counterstained with 0.5 mgml
21 Hoechst 33342
(Invitrogen) for 20 minutes and washed in PBS-T. To quench
tissue fluorescence, slides were incubated with 0.1% Sudan Black
B (BDH, Poole, UK) in 70% ethanol for 20 minutes [82], washed
in PBS-T and mounted using a solution of 80% glycerol in
0.5 mM Tris buffer (pH 7.2). Slides were stored at 4uC until image
acquisition. In order to identify the predominating MQ popula-
tions in sub-acute and chronically injured tendon, dual staining
using antibodies against CD14 and CD206 was performed. Due to
the lack of commercially available antibodies to Lipoxin A4 for
immunofluorescence, Annexin A1 was chosen as an alternative
ligand for FPR2/ALX. Dual staining was also performed using
antibodies against CD14 and FPR2/ALX or CD14 and Annexin
A1 to determine expression on tenocytes and M1MQ.
Effect of pro-inflammatory mediators on FPR2/ALX
expression
As evaluation of injured tendon sections revealed differences in
FPR2/ALX expression, we assessed the impact of pro-inflamma-
tory mediators on FPR2/ALX expression in vitro. Macroscopically
normal SDFTs from an equine abattoir were harvested from 3
Thoroughbred horses aged between 2 and 15 years (mean age 8
years). Tendons were cut into 0.4 cm
3 explants (300 mg630 mg)
under aseptic conditions and incubated at 37uC and 5% CO2
under humidified atmosphere in 3 ml Dulbecco’s Modified Eagle
Medium (PAA, Somerset, UK) containing 1% Penicillin and
Streptomycin (PAA) without foetal calf serum. Samples were
stimulated with either 5 ng ml
21 human recombinant IL-1b
(Merck, CalbiochemH, Nottingham UK), 1.0 mM PGE2 (Sigma
Aldrich) or a combination of 5 ng ml
21 IL-1b and 1.0 mM PGE2.
Non-stimulated (vehicle only) samples served as controls. Tendon
explants and media were harvested immediately (time 0) and 12,
24 and 72 hours after stimulation. Media samples were stored at
280uC prior to processing for determination of LXA4 levels.
Tendon explants were snap frozen in chilled (280uC) n-hexane,
embedded in OCT and stored at 280uC until processing for
immunofluorescent analysis. Cryosections were cut and mounted
onto poly-L-lysine coated slides as described above. Sections were
allowed to dry for 2 hours at room temperature prior to storage at
280uC. Cryosections were probed with a 1:100 diluted primary
mouse monoclonal FPR2/ALX antibody (Lipoxin A4 receptor,
IgG1, AbCam) and secondary goat anti-mouse IgG1 (Southern
Biotech), followed by Hoechst nuclear counter stain. Tissue
fluorescence was quenched with Sudan Black B (BDH) and
sections were mounted for imaging as before.
Image acquisition and analysis
Images for histology sections were acquired using a Leica
DM4000B microscope with a DC500 camera (Leica Microsys-
tems, Milton Keynes, UK). All immunofluorescent images were
recorded on a Leica SP5 confocal microscope (Leica Micro-
systems) using a 636 oil immersion objective (NA=1.4). For 2-
dimensional images a minimum of 5 random high power field
images were acquired per tissue section per horse (for analysis of
normal and naturally diseased tendon), or per experimental
condition for each time point (in vitro explant experimental system).
Antigen expression was automatically quantified by measurement
of the area of immunopositive cells in each image. As we expected
this area to vary with the cellular density in the tendon, the area of
immunopositive cells was standardised by expressing it as a ratio to
the total area of counterstained nuclei, which was used as a
measure of cellular density. Quantitative analysis was performed
on 2-dimensional images which were acquired using a 636 oil
immersion objective for pan MQ, FPR2/ALX and Annexin A1
antibody treated cryosections. In order to determine the
predominant MQ populations by dual antibody labelling, a ratio
of areas (mm
2) of positive immuno-reactivity for CD14 (red) versus
CD206 (green) was determined from 2-dimensional images
acquired from 5 horses each with either sub-acute or chronic
tendon injury. In each case, the area of positive staining was
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Cambridge, UK). Positive staining was defined as a signal being
over a predetermined threshold for each stain. Groups of less than
4 continuous positive pixels were considered noise and excluded
from the measurements. Z stack images were acquired using either
206 or 636 objectives with 2566256 matrix and slice thickness
between 0.18–0.25 mm. Three-dimensional image reconstructions
were created using Volocity software (PerkinElmer).
Measurement of lipoxin A4 in media from stimulated
tendon explants
In addition to assessing FPR2/ALX expression in tendon
explants stimulated with IL-1b or PGE2, media were analysed to
determine release of the ligand LXA4. LXA4 was separated from
the supernatant by passage through Bond Elut C18 columns
(Agilent Technologies, CA, USA) followed by elution with methyl
formate. Samples were evaporated to dryness in a stream of
nitrogen and resuspended in extraction buffer from a LXA4
ELISA kit (Neogen Corp, Lexington, KY, USA). LXA4 levels in
media samples were determined using this ELISA in duplicate
wells according to the manufacturer’s instructions. The ELISA kit
is specific for LXA4 showing minimal cross-reactivity [LXA4
100%, Lipoxin B4 1.0%, 15-hydroxyeicosatetraenoic acid (HETE)
0.1%, 5-HETE ,0.1% and 12 HETE ,0.1%].
Statistics
For normal and injured tendons, statistical analyses were
performed on 2-dimensional confocal images using GraphPad
Prism 5 (GraphPad Software Inc., San Diego, CA). Normality was
tested using a Kolmogorov-Smirnov test. Kruskal-Wallis with post
hoc Dunn’s multiple comparison tests were performed to
determine differences between normal, sub-acute and chronic
injured tendons for CD172a (pan) MQ, FPR2/ALX and Annexin
A1 staining. Mann Whitney tests were used to compare expression
of CD14
highCD206
low (M1MQ) and CD14
lowCD206
high (M2MQ)
in sub-acute and chronic injured tendons. To determine the
predominating MQ phenotype in both sub-acute and chronic
injury stages, a Student’s t test was performed on log transformed
ratios of areas of positive immuno-reactivity for M1:M2 MQ. In all
cases, the P value was considered significant if below 0.05.
For FPR2/ALX explant experiments, statistical analyses for
explant experiments were performed using SPSS PASW Statistics
18 (SPSS Inc Illinois, USA). A linear mixed effect model was used
to assess FPR2/ALX expression on natural log transformed data
to account for repeat measures of experimental condition and time
points 0, 12, 24 and 72 hours. A linear model was used to assess
LXA4 levels in media to account for effects of horse, experimental
condition, time and interaction between condition and time.
Linear contrast was then used on each data set to assess the
differences between each experimental condition and time point.
P,0.05 was considered statistically significant.
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